MRI Studies of the Hydrodynamics in a USP 4 Dissolution Testing Cell

Journal of Pharmaceutical Sciences

Volumn 100, Issue 3, 2011, Pages 976-991

  Shiko, G ^a   Gladden, L F ^a   Sederman, A J ^a   Connolly, P C ^b   Butler, J M ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Controlled release; Dissolution; Dissolution testing; Hydrodynamics; in vitro models; in vitro in vivo correlations (IVIVC); Laminar flow; Magnetic resonance imaging (MRI); Physical characterization; USP apparatus 4 (flow through cell)

Indexed keywords

ARTICLE; DRUG SOLUBILITY; HYDRODYNAMICS; LAMINAR FLOW; MEDICAL LITERATURE; NUCLEAR MAGNETIC RESONANCE IMAGING; PULSATILE FLOW;

EID: 79251545798     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22343     Document Type: Article

References (78)

1. Food and Drug Administration. 1997. Guidance for industry: Dissolution testing of immediate release solid oral dosage forms. Silver Spring, MD: Center for Drug Evaluation and Research, pp 1-11
2. Food and Drug Administration. 1997. Guidance for industry: Extended release dosage forms development, evaluation and application of in vivo/in vitro correlations. Silver Spring, MD: Center for Drug Evaluation and Research, pp 1-20.
3. Jorgensen ED, Bhagwat D. 1998. Development of dissolution tests for oral extended-release products. Pharm Sci Technol Today 1: 128-135.
4. Azarmi S, Roa W, Lobenberg R. 2007. Current perspectives in dissolution testing of conventional and novel dosage forms. Int J Pharm 328: 12-21.
5. Food and Drug Administration. 2004. PAT-A framework for innovative pharmaceutical development, manufacturing, and quality assurance. Silver Spring, MD: Center for Drug Evaluation and Research, pp 1-19.
6. ICH. 2005. Q8: Pharmaceutical development. In ICH harmonised tripartite guideline. Geneva, Switzerland: ICH, pp 1-7.
7. ICH. 2006. Q9: Quality risk management. In ICH harmonised tripartite guideline. Geneva, Switzerland: ICH, pp 1-21.
8. ICH. 2007. Q10: Pharmaceutical quality system. In ICH harmonised tripartite guideline. Geneva, Switzerland: ICH, pp 1-15.
9. Khan MZI. 1996. Dissolution testing for sustained or controlled release oral dosage forms and correlation with in vivo data: Challenges and opportunities. Int J Pharm 140: 131-143.
10. Dressman J, Krämer J. 2005. Pharmaceutical dissolution testing. New York: Taylor & Francis
11. TM. Eur J Pharm Sci 17: 51-61.
12. Neubert A, Sternberg K, Nagel S, Harder C, Schmitz K-P, Kroemer HK, Weitschies W. 2008. Development of a vessel-simulating flow-through cell method for the in vitro evaluation of release and distribution from drug-eluting stents. J Control Release 130: 2-8.
13. Tingstad JE, Riegelman S. 1970. Dissolution rate studies I: Design and evaluation of a continuous flow apparatus. J Pharm Sci 59: 692-696.
14. Bhattachar SN, Wesley JA, Fioritto A, Martin PJ, Babu SR. 2002. Dissolution testing of a poorly soluble compound using the flow-through cell dissolution apparatus. Int J Pharm 236: 135-143.
15. Dressman JB, Vertzoni M, Goumas K, Reppas C. 2007. Estimating drug solubility in the gastrointestinal tract. Adv Drug Deliv Rev 59: 591-602.
16. Vertzoni M. 2008. The development of biorelevant dissolution methods. In JPAG symposium: The current state of dissolution testing, December 2, 2008, London, UK.
17. Shciller C, Fröhlich C-P, Giessmann T, Siegmund W, Monnikes H, Hösten N, Weitschies W. 2005. Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging. Aliment Pharm Ther 22: 971-979.
18. Melia CD, Rajabi-Siahboomi AR, Bowtell RW. 1998. Magnetic resonance imaging of controlled release pharmaceutical dosage forms. Pharm Sci Technol Today 1: 32-39.
19. Richardson JC, Bowtell RW, Mader K, Melia CD. 2005. Pharmaceutical applications of magnetic resonance imaging (MRI). Adv Drug Deliv Rev 57: 1191-1209.
20. Zeitler JA, Gladden LF. 2008. In-vitro tomography and non-destructive imaging at depth of pharmaceutical solid dosage forms. Eur J Pharm Biopharm 71: 2-22.
21. Fyfe CA, Blazek-Welsh AI. 1997. Investigation of hydrogel formation from hydroxypropylmethylcellulose (HPMC) by NMR spectroscopy and NMR imaging techniques. Macromolecules 30: 6230-6237.
22. Hyde TM, Gladden LF. 1997. Simultaneous measurement of water and polymer concentration profiles during swelling of poly(ethylene) oxide using magnetic resonance imaging. Polymer 39: 811-819.
23. Snaar JEM, Bowtell R, Melia CD, Morgan S, Narasimhan B, Peppas NA. 1998. Self-diffusion and molecular mobility in PVA-based dissolution-controlled systems for drug delivery. Magn Reson Imaging 16: 691-694.
24. Fyfe CA, Blazek-Welsh AI. 2000. Quantitative NMR imaging study of the mechanism of drug release from swelling hydroxypropylmethylcellulose tablets. J Control Release 68: 313-333.
25. 1H NMR and MRI methods. Eur J Pharm Biopharm 59: 299-306.
26. Masaro L, Ousalem M, Baille WE, Lessard D, Zhu XX. 1999. Self-diffusion studies of water and poly(ethylene glycol) in solutions and gels of selected hydrophilic polymers. Macromolecules 32: 4375-4382.
27. Harding S, Baumann H, Gren T, Seo A. 2000. NMR microscopy of the uptake, distribution and mobility of dissolution media in small, sub-millimetre drug delivery systems. J Control Release 66: 81-99.
28. Katzhendler I, Mader K, Friedman M. 2000. Structure and hydration properties of hydroxypropyl methylcellulose matrices containing naproxen and naproxen sodium. Int J Pharm 200: 161-179.
29. Tritt-Goc J, Pislewski N. 2002. Magnetic resonance imaging study of the swelling kinetics of hydroxypropylmethylcellulose (HPMC) in water. J Control Release 80: 79-86.
30. Fahie BJ, Nangia A, Chopra SK, Fyfe CA, Grondey H, Blazek A. 1998. Use of NMR imaging in the optimization of a compression-coated regulated release system. J Control Release 51: 179-184.
31. Djemai A, Sinka IC. 2006. NMR imaging of density distributions in tablets. Int J Pharm 319: 55-62.
32. Collins JHP, Gladden LF, Hardy IJ, Mantle MD. 2007. Characterizing the evolution of porosity during controlled drug release. Appl Magn Reson 32: 185-204.
33. Busignies V, Porion P, Leclerc B, Evesque P, Tchoreloff P. 2008. Application of PGSTE-NMR technique to characterize the porous structure of pharmaceutical tablets. Eur J Pharm Biopharm 69: 1160-1170.
34. Sutch JCD, Ross AC, Kockenberger W, Bowtell RW, MacRae RJ, Stevens HNE, Melia CD. 2003. Investigating the coating-dependent release mechanism of a pulsatile capsule using NMR microscopy. J Control Release 92: 341-347.
35. Fyfe CA, Grondey H, Blazek-Welsh AI, Chopra SK, Fahie BJ. 2000. NMR imaging investigations of drug delivery devices using a flow-through USP dissolution apparatus. J Control Release 68: 73-83.
36. Kulinowski P, Dorozynski P, Jachowicz R, Weglarz WP. 2008. An integrated system for dissolution studies and magnetic resonance imaging of controlled release, polymer-based dosage forms: A tool for quantitative assessment of hydrogel formation processes. J Pharm Biomed 48: 685-693.
37. Knörgen M, Spielmann RP, Abdalla A, Metz H, Mäder K. 2010. Non-invasive MRI detection of individual pellets in the human stomach. Eur J Pharm Biopharm 74: 120- 125.
38. Weitschies W, Blume H, Mönnikes H. 2010. Magnetic marker monitoring: High resolution real-time tracking of oral solid dosage forms in the gastrointestinal tract. Eur J Pharm Biopharm 74: 93-101.
39. Metz H, Mäder K. 2008. Benchtop-NMR and MRI: A new analytical tool in drug delivery research. Int J Pharm 364: 170- 175.
40. 2 generation by benchtop MRI and its relation to drug release and floating strength. Eur J Pharm Biopharm 69: 708-717.
41. Malaterre V, Metz H, Ogorka J, Gurny R, Loggia N, Mäder K. 2009. Benchtop-magnetic resonance imaging (BT-MRI) characterization of push-pull osmotic controlled release systems. J Control Release 133: 31-36.
42. Nott KP. 2009. Magnetic resonance imaging of tablet dissolution. Eur J Pharm Biopharm 74: 78-83.
43. Coulson JM, Richardson JF, Backhurst JR, Harker JH. 1997. Coulson and Richardson's chemical engineering. In Fluid flow, heat transfer and mass transfer. Vol. 1. 5th ed. Oxford, UK: Butterworth Heinemann pp 48-120.
44. Garner FH, Keey RB. 1958. Mass-transfer from single solid spheres I: Transfer at low Reynolds numbers. Chem Eng Sci 9: 119-129.
45. Cammarn SR, Sakr A. 2000. Predicting dissolution via hydrodynamics: Salicylic acid tablets in flow through cell dissolution. Int J Pharm 201: 199-209.
46. Garner FH, Keey RB. 1959. Mass-transfer from single solid spheres II: Transfer in free convection. Chem Eng Sci 9: 218-224.
47. Nicklasson M, Wennergren B, Lindberg J, Persson C, Ahlgren R, Palm B, Pettersson A, Wenngren L. 1987. A collaborative in vitro dissolution study using the flow-through method. Int J Pharm 37: 195-202.
48. Wennergren B, Lindberg J, Nicklasson M, Nilsson G, Nyberg G, Ahlgren R, Persson C, Palm B. 1989. A collaborative in vitro dissolution study: Comparing the flow-through method with the USP paddle method using USP prednisone calibrator tablets. Int J Pharm 53: 35-41.
49. Bielen N. 2002. Performance of USP calibrator tablets in flow-through cell apparatus. Int J Pharm 233: 123-129.
50. Morihara M, Aoyagi N, Kaniwa N, Katori N, Kojim S. 2002. Hydrodynamic flows around tablets in different pharmacopeial dissolution tests. Drug Dev Ind Pharm 28: 655.
51. Bloomfield MS, Butler WC. 2000. Robustness testing, using experimental design, of a flow-through dissolution method for a product where the actives have markedly differing solubility properties. Int J Pharm 206: 55-61.
52. Perng C-Y, Kearney AS, Palepu NR, Smith BR, Azzarano LM. 2003. Assessment of oral bioavailability enhancing approaches for SB-247083 using flow-through cell dissolution testing as one of the screens. Int J Pharm 250: 147-156.
53. Crail DJ, Tunis A, Dansereau R. 2004. Is the use of a 200 ml vessel suitable for dissolution of low dose drug products? Int J Pharm 269: 203-209.
54. Pal A, Indireshkumar K, Schwizer W, Abrahamsson B, Fried M, Brasseur JG. 2004. Gastric flow and mixing studied using computer simulation. Proc R Soc Lond B 271: 2587-2594.
55. Kukura J, Baxter JL, Muzzio FJ. 2004. Shear distribution and variability in the USP apparatus 2 under turbulent conditions. Int J Pharm 279: 9-17.
56. Gao Z, Moore TM, Smith AP, Doub WH, Westenberger BJ. 2007. Studies of variability in dissolution testing with USP apparatus 2. J Pharm Sci 96: 1794-1801.
57. D'Arcy DM, Healy AM, Corrigan OI. 2009. Towards determining appropriate hydrodynamic conditions for in vitro-in vivo correlations using computational fluid dynamics. Eur J Pharm Sci 37: 291-299.
58. Kakhi M. 2009a. Mathematical modeling of the fluid dynamics in the flow-through cell. Int J Pharm 376: 22-40.
59. D'Arcy DM, Liu H-B, Bradley G, Healy AM, Corrigan OI. 2010. Hydrodynamic and species transfer simulations in the USP 4 dissolution apparatus: Considerations for dissolution in a low velocity pulsing flow. Pharm Res 27: 246-258.
60. USP. 2009. United States Pharmacopeia 32. Rockwell, MD: United States Pharmacopeial Convention.
61. Pope JM, Yao S. 1993. Quantitative NMR imaging of flow. Concept Magn Reson 5: 281-302.
62. Fukushima E. 1999. Nuclear magnetic resonance as a tool to study flow. Annu Rev Fluid Mech 31: 95-123.
63. Callaghan PT, Codd SL, Seymour JD. 1999. Spatial coherence phenomena arising from translational spin motion in gradient spin echo experiments. Concept Magn Reson 11: 181- 202.
64. Blümich B. 2000. NMR imaging of materials. Oxford, UK: Oxford University Press.
65. Caprihan A, Fukushima E. 1990. Flow measurements by NMR. Phys Rep 198: 195-235.
66. Uludag Y, Powell RL, McCarthy MJ. 2004. Effects of periodic flow fluctuations on magnetic resonance flow images. AIChE J 50: 1662-1671.
67. Markl M, Hennig J. 2001. Phase contrast MRI with improved temporal resolution by view sharing: k-space related velocity mapping properties. Magn Reson Imaging 19: 669-676.
68. Elkins CJ, Alley MT. 2007. Magnetic resonance velocimetry: Applications of magnetic resonance imaging in the measurement of fluid motion. Exp Fluids 43: 823-858.
69. Huntley JM, Martin TW, Mantle MD, Shattuck MD, Sederman AJ, Wildman RD, Gladden LF, Halliwell NA. 2007. NMR measurements and hydrodynamic simulations of phase-resolved velocity distributions within a three-dimensional vibrofluidized granular bed. Proc R Soc A 463: 2519- 2542.
70. Mantle MD, Sederman AJ, Gladden LF, Huntley JM, Martin TW, Wildman RD, Shattuck MD. 2008. MRI investigations of particle motion within a three-dimensional vibro-fluidized granular bed. Powder Technol 179: 164-169.
71. Fluid Metering Inc. 2009a. FMI 2009 catalog. Syosset, NY: Fluid Metering Inc. Accessed at.
72. Pitts DR, Sissom LE. 1998. Schaum's outline of theory and problems of heat transfer. In Natural convection. 2nd ed. New York: McGraw Hill, pp 221-232.
73. White FM. 1994. Chapter 6: Viscous flow in ducts, and Chapter 7: Boundary layer flows. In Fluid mechanics. 3rd ed. New York: McGraw Hill, pp 294-370, pp 387-433.
74. FMI. 2009. Private communication. Syosset, NY: Fluid Metering Inc.
75. Kakhi M 2009. Classification of the flow regimes in the flow-through cell. Eur J Pharm Sci 37: 531-544.
76. Stuart JJ. 1963. Fluid motion memoirs: Boundary layers, In Hydrodynamics stability. Oxford, UK: Oxford University Press, pp 492-578.
77. Schlichting H. 1968. Boundary layer theory. In Origin of turbulence I. 6th ed. New York: McGraw Hill, pp 431-457.
78. Davidson PA. 2004. Turbulence: An introduction for scientists and engineers. In The ubiquitous nature of turbulence. Oxford, UK: Oxford University Press, pp 1-24.